Kornimate/medical-research-clean huggingface dataset:
stress-reactivity and cannabis use in cannabis-using older adults

Conditions: Cannabis Use

Summary: the goal of the study is to evaluate how cannabis use affects memory and thinking skills and response to stress in older adults. the study will also relate cannabis use to alzheimer's disease (ad) biomarkers (measurable substances in blood that indicate condition), and test whether sex and hormones play a role in these effects. the study is recruiting adults between the ages of 50 and 80 who use cannabis products on a regular basis. study participation will last about two weeks.


Eligibility criteria:
inclusion criteria: * age 50-80. * women must be \>1 year post-menopausal. * english as a first/primary language. * functional visual and auditory acuity (aided or unaided) to complete tests. * capacity to independently provide informed consent and function at an intellectual level sufficient to allow completion of all instruments. * currently meets dsm-5 criteria for cud or uses cannabis at least 4 days per week * consent to abstain from alcohol and cannabis use for \>12 hours prior to study visit (day 0), and tsst (day 8). * consent to abstain from all drugs other than cannabis or nicotine for the duration of the study. exclusion criteria: * meet dsm-5 criteria for moderate or severe alcohol or substance use disorder (other than nicotine or cannabis) within the last 12 months. * history of major neurocognitive disorder or developmental disorder per dsm-5. * a telephone interview for cognitive status (tics) score of less than or equal to 22. * significant or unstable medical condition/s that impact cognition as deemed by study investigators, such as active significant cardiac, cerebrovascular, neoplastic, infectious, or metabolic disease, or longstanding and intractable severe mental illness (e.g. schizophrenia spectrum disorder, bipolar disorder). * daily use of medications that adversely impact cognition in aging (i.e. anticholinergics and sedatives). * current suicidal or homicidal ideation/risk. * unable to complete/comply with procedures or pose threat to research staff. * standard mri contraindications (e.g., implants, claustrophobia). * women who are pregnant, nursing, or of childbearing potential and not practicing and effective means of birth control.
bleed free treatment of menopausal symptoms with new ultra low dose hormonal combinations

Conditions: Menopause; Menopausal Vasomotor Symptoms

Summary: this trial is conducted in europe. postmenopausal women with moderate to severe hot flashes have been recruited into the trial. the earliest effect of ultra low dose hrt (hormone replacement therapy) on frequency and severity of menopausal symptoms, bleeding patterns and safety of different hormonal combinations will be evaluated and compared to placebo over the six month treatment period.


Eligibility criteria:
inclusion criteria: * postmenopausal status * subject should have had a minimum of 7 moderate to severe hot flushes per day, or a minimum of 50 moderate to severe hot flushes per week, during the last 2 weeks of the run-in (screening) period. * subject with an intact uterus exclusion criteria: * in accordance with existing labelling for estrogen/progestogen combinations * body mass index (bmi) \> 35.0 kg/m2 * known alcohol or drug abuse, heavy smoking (more than 20 cigarettes a day) * currently using steroid hormones (except topical or inhalation glucocorticoid preparations) and drugs known to influence estrogen metabolism such as barbiturates, phenytoin, rifampicin, carbamazepin

Keywords: hot flashes
dose-escalation, safety, pharmacokinetics study of ave8062 combined with bevacizumab in patients with advanced solid tumors

Conditions: Neoplasms, Malignant

Summary: primary objective: - to determine the maximum administered dose (mad) and the maximum tolerated dose (mtd) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of related dose limiting toxicities (dlts). secondary objectives: * to assess the overall safety profile of the combination * to characterize the pharmacokinetic (pk) profile of both ombrabulin and bevacizumab when given in combination * to evaluate preliminary evidence of anti-tumor activity * to assess the pharmacodynamic effect using (dynamic contrast enhanced ultra-sound) dce-us, measuring biomarkers

the duration of the study for each patient will include an up to 28-day screening phase, 21-day study treatment cycles, an end of treatment visit with a follow-up period. each patient will participate in only one dose group and will receive ave8062 with bevacizumab every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or investigator's decision.

Eligibility criteria:
inclusion criteria: * histologically or cytologically proven solid malignant tumor at the first diagnosis with the exception of squamous non small cell lung cancer (nsclc). * advanced neoplastic disease (i.e. metastatic or locally unresectable advanced disease) * presence of one measurable lesion at baseline in the mtd expanded cohort exclusion criteria: * ecog (eastern cooperativeoncology group) performance status \> 1 * concurrent treatment with any other anticancer therapy * pericardial effusion requiring intervention (drainage) * history of brain metastasis, spinal cord compression or carcinomatous meningitis or new evidence of brain metastasis on screening computed tomography (ct) or magnetic resonance imaging (mri) scan * diagnosis of squamous non squamous cell lung cancer (nsclc) or with mixed cell type with predominant squamocellular histology * hormone sensitive prostate cancer * abdominal radiotherapy * major surgery within the last month of study enrollment or surgical wound not fully healed before study enrollment * high cumulative doses of anthracycline * inadequate organ function * inadequate hematology function or poor bone marrow reserve * any of the following within 6 months prior to study enrollment: peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease and diverticulitis * any history or underlying cardiac condition that may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
efficacy of an exercise intervention to decrease depressive symptoms in veterans with hepatitis c

Conditions: Hepatitis C; Depression

Summary: in this study, depressed veterans with hepatitis c will be randomly assigned to the control group or to the exercise intervention group. the exercise intervention is designed to begin slowly for most participants and to progress within each participant's target heart rate range for moderate intensity exercise. the exercise intervention is a 12 week home based walking program. ideally individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. however, the duration and relative intensity will be tailored for each individual. central hypothesis veterans who receive the exercise intervention will be significantly less symptomatic for depression than veterans in the control group.


Eligibility criteria:
inclusion criteria: * male or female, age 18 or older * documentation of positive hepatitis c status as indicated by a detectable hcv viral load by polymerase chain reaction * mild to moderate depressive symptoms as evidenced by a bdi ii score of ≥ 14 * able to read and understand english * written/signed informed consent specific to this protocol * being sedentary that is , less than 30 minutes of planned low to moderate intensity exercise 2 days per week exclusion criteria: * suicidal ideations * current interferon therapy or planning to begin interferon therapy during the next three months * diagnosis of bipolar disorder, schizophrenia, or post traumatic stress disorder * any medical condition, disorder, or medication that contraindicates participation in a mild to moderate intensity walking program

Keywords: hepatitis c depression exercise
a study of ly3361237 in participants with psoriasis

Conditions: Psoriasis

Summary: the main purpose of this study is to learn more about the safety and tolerability of ly3361237 and any side effects that might be associated with it when given to participants with psoriasis. ly3361237 will be administered by injections just under the skin. the study will last up to 41 weeks and may include up to 15 visits to the study center.


Eligibility criteria:
inclusion criteria: * have chronic plaque psoriasis for at least 6 months * be willing and able to undergo skin biopsies * body mass index (bmi) within the range of 18 to 40 kilograms per meter squared (kg/m²) * female participants must agree to use birth control during the study exclusion criteria: * have had certain types of infection within the last six months * have a clinically significant active infection, or recent acute active infection within the last 30 days * have other serious or unstable illnesses * have a history of organ or bone marrow transplant * have received any live vaccine within the last 4 weeks prior to screening * have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day 1 * have received topical psoriasis treatment within 14 days prior to study day 1 * have excessive skin exposure or use tanning booths for at least 4 weeks prior to study day 1
chronic inflammation after obesity surgery

Conditions: Obesity

Summary: to evaluate the impact of obesity surgery on chronic inflammation.

a retrospective study to compare the impact of laparoscopic sleeve gastrectomy (lsg), laparoscopic roux-en y- gastric bypass (lrygb) and laparoscopic omega-loop gastric bypass (lolgb) on chronic inflammation and metabolic syndrome.

Eligibility criteria:
inclusion criteria: * bmi \> 35kg/m² and obesity-related disease or bmi \> 40kg/m² exclusion criteria: * acute inflammation during laboratory examination

Keywords: chronic inflammation fatty liver index
easing psychosocial burden for informal caregivers

Conditions: Glioblastoma

Summary: the overall goal of this study is to determine the best time to offer meaning-centered psychotherapy (mcp), an intervention that has proven to be helpful in improving spiritual well-being and decreasing existential distress among patients with advanced cancer, to caregivers. (mcp has also been shown to be an appropriate method of attending to the palliative or comfort care needs of caregivers of patients with cancer. studies show that the psychological burden associated with caring for a patient with advanced cancer is often greater than that experienced by the patients themselves.) the investigators would also like to find out about caregivers initial impressions of mcp-c, meaning-centered psychotherapy for cancer caregivers, so that the intervention can be adjusted to meet the unique needs of caregivers of patients with glioblastoma.


Eligibility criteria:
inclusion criteria: part i focus group gbm informal caregivers (ics): * english-speaking as english proficiency screener and in the best judgment of the consenting professional. this is due to the focus groups being managed in english and the use of certain validated questionnaires only being available in english. * age \> 18 * ic to an mskcc patient with gbm who died a year or more ago part ii randomized intervention of gbm ics: * english-speaking as per english proficiency screener and in the best judgment of the consenting professional * current ics to a patient with gbm * age ≥ 18 * score of \> 4 on the distress thermometer (dt) and indication that this distress is related in some way to the caregiving role per self-report exclusion criteria: * in the judgment of the consenting professional, clinician or pi and/or as per medical record, severe psychopathology or cognitive impairment likely to interfere with the participation or completion of the protocol or ability to provide meaningful information * another family member of caregiver to the same patients is currently enrolled in the study * ultimately, if interested, all caregivers who decline participation or are ineligible for the study for any reason, including because another caregiver of the patient is currently enrolled in the study, will be offered referrals to the mskcc counseling center and to local mental health providers

Keywords: cancer caregivers caregiver caregivers memorial sloan kettering cancer center 18-075
conditioned pain modulation in localized vs widespread chronic low back pain

Conditions: Chronic Low-back Pain

Summary: this study aims to compare function of the body's endogenous pain modulation system between people with localized low back pain versus widespread body pain. endogenous pain modulation refers to the body's natural ability to inhibit one pain stimulus by applying a second pain stimulus. this study will assess pain inhibition by measuring pressure pain thresholds at the low back before and during cold water hand immersion. the researchers hypothesize that those with widespread body pain will have worse functioning of pain inhibition compared to those with localized low back pain only. the results may provide insights into personalized chronic pain management approaches.

chronic low back pain (clbp) is highly prevalent worldwide. impairments in conditioned pain modulation (cpm) have been documented in clbp populations. cpm refers to endogenous pain inhibition, where one noxious stimulus inhibits pain from a second noxious stimulus. this relies on descending inhibitory pathways. however, it is unknown whether cpm alterations differ between individuals with localized versus widespread mechanical pain hypersensitivity. the aim of this cross-sectional quantitative sensory testing study is to compare cpm function between localized and widespread clbp subgroups. a sample of 75 adults with clbp of at least 3 months duration will be recruited from a chronic pain clinic. based on pressure pain threshold mapping at the low back and distal sites, participants will be classified as having localized or widespread mechanical hyperalgesia.

Eligibility criteria:
inclusion criteria: * ages 18-60 years * chronic lbp \>3 months * average lbp intensity ≥4/10 exclusion criteria: * known lbp pathologies * previous lumbar surgery * neuropathic lbp * comorbid generalized pain conditions
bioequivalency study of buprenorphine hydrochloride 8 mg tablet under fasted conditions

Conditions: Opioid-Related Disorders

Summary: the objective of this study was to prove the bioequivalence of buprenorphine hcl 8 mg tablet under fasted conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. history of allergic or adverse response to buprenorphine hydrochloride or any comparable or similar product.
all-cause and diseases-specific mortality of high-risk hpv infection

Conditions: HPV Infection

Summary: the corresponding prevention strategies and treatment routes of hpv infection can be provided through investigating causes of death due to hpv infection and specialized diseases.

anxiety and panic about hpv infection have become common phenomena in tumor screening. transitional and useless diagnosis and treatment caused by hpv infection are also common, affecting women's physical and mental health and health economic level. if the investigators can understand the causes of death related to hpv infection and specialized diseases, the investigators can provide corresponding prevention strategies and treatment routes from the level of health policies and individual methods and mechanisms, and also alleviate the related panic caused by hpv infection.

Eligibility criteria:
inclusion criteria: 1. female participate in at least once cervical cancer screening with clear information of hpv dna test results; 2. having clear identification (id number or others) that can be retrieved in the cause of death database. exclusion criteria: cases that do not fully meet all inclusion criteria are used as exclusion criteria.
carcinologic speech severity index

Conditions: Head and Neck Cancer

Summary: the hypothesis of the present study is that an automatic assessment technic can measure the impact of the speech disorders on the communication abilities giving a severity index of speech in patients treated for head and neck and particularly for oral and pharyngeal cancer.


Eligibility criteria:
inclusion criteria: * oral and pharyngeal cancer t2 to t4 for having a wide dynamic of deficit * treatment by surgery and/or radiotherapy and/or chemotherapy * delay after the end of the treatment of minimum 6 months. exclusion criteria: * patients with a previous speech disorders (ie stuttering... ) * patients not able to perform the whole task

Keywords: linguistic quality of life
pilot study of safety and efficacy of sodium phenylbutyrate in spinocerebellar ataxia type 3

Conditions: Spinocerebellar Ataxia Type 3

Summary: design: pilot, phase ii, double-blind, placebo-controlled study justification: in the literature one does not find a pharmacological treatment that changes the natural history of spinocerebellar ataxtia type 3 (sca3). patients with this disease invariably become dependent. objectives i. to determine safety and tolerability of phenylbutyrate in patients with sca3. ii. to provide early subsidies on the efficacy of phenylbutyrate in sca3. duration: 12 months of a double-blind study. place of realization: hospital de clínicas de porto alegre, brazil. number of patients: 20 patients. concomitant medications: there are no concomitant medications that are prohibited unless they affect safety parameters of this study (hemogram and platelets; fasting serum glucose, ast, alt, gamma-gt, bilirubins, prothrombin time, creatinine, urea, na, k, chlorides and arterial gasometry; electrocardiogram and echocardiogram). medications under investigation: powdered sodium phenylbutyrate in sachets containing each 3g. at the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events. outcomes primary safety outcome: the number of adverse events, interruptions and dose reductions in the two groups (cases and controls). efficacy outcomes: efficacy outcomes are the following scores in both groups: nessca, sara, barthel, bdi, and whoqol.


Eligibility criteria:
inclusion criteria: 1. all patients shall have their molecular diagnosis confirmed and expanded polyglutamine tract (cag) measures already determined. 2. patients still able to walk with until 8 years of disease duration, and 3. patients aged 16 years or over will be invited to participate in the study. exclusion criteria: 1. they show electrocardiogram ou echocardiographic alterations suggestive of heart insufficiency at baseline; 2. their serum creatinine levels are higher than 1.2 mg/dl, with the confirmation of renal insufficiency due to the rate of glomerular filtration; 3. they show a history of hypersensibility to sodium phenylbutyrate, and if 4. they (men and women) do not agree to use a reliable contraceptive method during the entire study period and for three months after its end.

Keywords: sca spinocerebellar ataxia sodium phenylbutyrate machado-joseph disease treatment
molemapper, visiomed, and confocal microscopy in screening participants for melanoma

Conditions: Cutaneous Melanoma; Melanocytic Nevus; Skin Carcinoma

Summary: this trial studies how well molemapper, visiomed, and confocal microscopy work in screening participants for melanoma. analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.

primary objective: i. to assess the clinical utility of clinical images, digital dermoscopy images and in-vivo confocal microscopy for teledermatology. secondary objective: i. to incorporate in vivo confocal images into the triage system in order to determine to what degree the information gathered in this modality changes the classification of a lesion assigned by a licensed dermatologist. tertiary objective: i. to assess the potential improvement of virtual patient triage when adding digital dermoscopy images to clinical images presented by patients to their provider (via e-visit or e-consult). outline: participants undergo imaging of suspicious moles via smartphone application (app) molemapper/sklip app/native smartphone camera app, digital dermoscopy, and confocal microscopy. participants then receive lidocaine subcutaneously (sc) and undergo shave or punch biopsy of suspected melanomas. after completion of study intervention, patients are followed up within 1 week.

Eligibility criteria:
inclusion criteria: * persons who participate in the free skin cancer screening at the pdx skincare festival at oregon health \& science university (ohsu) in 2021/2022 (date pending) and are informed by a provider that they have a pigmented lesion for which a biopsy is recommended are potentially eligible to participate in this study. * persons who participate in the free skin cancer screening at the war on skin cancer event at ohsu in 2021/2022 (date pending) or other dates and locations and are informed by a provider that they have a clinically benign or atypical nevi are eligible to participate in the imaging portion of this study. no biopsy will be offered to these participants. * persons age 18-80 are eligible for the study * persons of any sex can be enrolled. * persons of any race are eligible but we anticipate that most participants will be non-hispanic whites due to the prevalence of melanoma and other skin cancers in this group. * only persons who can provide signed statement of informed consent will be enrolled. * persons who are identified in ohsu dermatology clinics or through ohsu e-visit and e-consult platforms as having a skin lesion in need of a biopsy for skin cancer * persons identified via the melanoma community registry (mcr) (irb approved: 00010561) exclusion criteria: * allergy to the anesthetic (lidocaine).
postpartum hypertension: remote patient monitoring

Conditions: Hypertension, Pregnancy-Induced

Summary: the purpose of this study is to see if honeywell genesis android touch bluetooth system (mobile health) can improve patient satisfaction and quality of care provided to women experiencing complications due to high blood pressure during pregnancy.

for six weeks postpartum, patients will use honeywell genesis android touch bluetooth system to record and submit their daily blood pressure and weight measurements to a mobile health nurse and research team. subjects will be provided with the kit (honeywell tablet, mobile hot spot, blood pressure cuff, and scale) at no cost. subjects will participate in video telehealth visits at 48 hours and 7 days after discharge to help provide management for hypertension related issues.

Eligibility criteria:
inclusion criteria: * hypertensive disorders of pregnancy including gestational, chronic, or preeclampsia diagnosed in the antenatal (primary admission for delivery of the baby (planned or due to hypertension) or postpartum period as determined by systolic blood pressure (sbp) greater than 140 or diastolic blood pressure (dbp) greater than 90 on two occasions 4 hours apart. * gestational age at time of delivery greater than 23 weeks gestation * postpartum with persistent sbp greater than 140 or dbp greater than 90 on two occasions 4 hours apart (to enroll would be prior to discharge from initial postpartum hospital stay). * primary hospital admission for the delivery of the neonate(s). exclusion criteria: * inability to obtain informed consent